Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSK | P41240 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 8/20 | 0.60 |
| ▸ | BCR | P11274 | 5/20 | 0.60 |
| ▸ | LYN | P07948 | 3/20 | 0.60 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.60 |
| ▸ | BRAF | P15056 | 3/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | RET | P07949 | 1/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | ARAF | P10398 | 1/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.60 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.60 |
| ▸ | ABL2 | P42684 | 1/20 | 0.60 |
| ▸ | FRK | P42685 | 1/20 | 0.60 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.60 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381985 | 0.90 | ABL1 (0.64) | CSKMAPK14ABL1BCRLYN | |
| SCHEMBL15381986 | 0.89 | CSK (0.64) | CSKMAPK14ABL1BCRLYN | |
| SCHEMBL588628 | 0.86 | KIT (0.73) | CSKMAPK14ABL1BCRLYN | |
| SCHEMBL588629 | 0.86 | KIT (0.73) | CSKMAPK14ABL1BCRLYN | |
| SCHEMBL3814061 | 0.85 | CSK (0.59) | CSKMAPK14ABL1BCRLYN | |
| SCHEMBL16755300 | 0.84 | KIT (0.74) | CSKMAPK14ABL1BCRLYN | |
| SCHEMBL16755289 | 0.84 | KIT (0.74) | CSKMAPK14ABL1BCRLYN | |
| SCHEMBL16755288 | 0.84 | KIT (0.74) | CSKMAPK14ABL1BCRLYN | |
| SCHEMBL3714239 | 0.84 | DDR1 (0.59) | CSKMAPK14ABL1BCRLYN | |
| SCHEMBL15859941 | 0.83 | CSK (0.56) | CSKMAPK14ABL1BCRLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396325-B1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | ORIBASE PHARMA (FR) | 2015-04-01 | — | — | EP | disclosed |
| EP-2396325-B1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | ORIBASE PHARMA (FR) | 2015-04-01 | — | — | EP | disclosed |
| US-8580815-B2 | Derivatives of azaindoles as inhibitors of protein kinases ABL and SRC | ORIBASE PHARMA (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ORIBASE PHARMA (FR) | 2011-12-22 | — | — | US | disclosed |
| EP-2396325-A1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | OriBase Pharma (FR) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092489-A1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | NOVA DECISION (FR) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010092489-A1 | DERIVATIVES OF AZAINDOLES AS INHIBITORS OF PROTEIN KINASES ABL AND SRC | NOVA DECISION (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312959-A1 | Derivatives of Azaindoles as Inhibitors of Protein Kinases ABL and SRC | ABL1, ABL2, SRC | CSK 232/4885MAPK14 167/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.